September 29, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Esperion Therapeutics Inc (NASDAQ:ESPR) shares over potential securities laws violations by Esperion Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Esperion Therapeutics Inc (NASDAQ:ESPR) concerning whether a series of statements by Esperion Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) grew from $16.34 per share in September 2014 to as high as $112.33 per share in March 2015.

On September 28, 2015, Esperion Therapeutics Inc provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration (FDA). Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) declined to as low as $18.07 per share on September 29, 2105.